Business Description
Heron Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US4277461020
Share Class Description:
FRA:AXD2: Ordinary SharesTotal Employee Number:
122Description
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.04 | |||||
Debt-to-Equity | 15.5 | |||||
Debt-to-EBITDA | -8.73 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -10 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.1 | |||||
3-Year EBITDA Growth Rate | 68.7 | |||||
3-Year EPS without NRI Growth Rate | 68.5 | |||||
3-Year FCF Growth Rate | 50.4 | |||||
3-Year Book Growth Rate | -14.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.97 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.06 | |||||
9-Day RSI | 32.73 | |||||
14-Day RSI | 30.19 | |||||
3-1 Month Momentum % | 8.56 | |||||
6-1 Month Momentum % | -34.68 | |||||
12-1 Month Momentum % | -59.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.53 | |||||
Quick Ratio | 1.51 | |||||
Cash Ratio | 0.49 | |||||
Days Inventory | 646.02 | |||||
Days Sales Outstanding | 200.04 | |||||
Days Payable | 91.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.5 | |||||
Shareholder Yield % | 35.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 71.12 | |||||
Operating Margin % | -6.94 | |||||
Net Margin % | -20.53 | |||||
EBITDA Margin % | -10.76 | |||||
FCF Margin % | -13.89 | |||||
OCF Margin % | -13.49 | |||||
ROA % | -12.69 | |||||
ROIC % | -8.25 | |||||
3-Year ROIIC % | 715.91 | |||||
ROC (Joel Greenblatt) % | -18.21 | |||||
ROCE % | -15.54 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 66.54 | |||||
PS Ratio | 0.49 | |||||
PB Ratio | 9.85 | |||||
Price-to-Tangible-Book | 11.77 | |||||
EV-to-EBIT | -9.62 | |||||
EV-to-Forward-EBIT | 43.95 | |||||
EV-to-EBITDA | -10.98 | |||||
EV-to-Revenue | 1.18 | |||||
EV-to-Forward-Revenue | 1.03 | |||||
EV-to-FCF | -8.54 | |||||
Price-to-GF-Value | 0.28 | |||||
Earnings Yield (Greenblatt) % | -10.4 | |||||
FCF Yield % | -26.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Heron Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ā¬) | 129.496 | ||
| EPS (TTM) (ā¬) | -0.154 | ||
| Beta | 3.2071 | ||
| 3-Year Sharpe Ratio | 0.27 | ||
| 3-Year Sortino Ratio | 0.5 | ||
| Volatility % | 79.4 | ||
| 14-Day RSI | 30.19 | ||
| 14-Day ATR (ā¬) | 0.024962 | ||
| 20-Day SMA (ā¬) | 0.39027 | ||
| 12-1 Month Momentum % | -59.41 | ||
| 52-Week Range (ā¬) | 0.33 - 1.874 | ||
| Shares Outstanding (Mil) | 189.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Heron Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Heron Therapeutics Inc Stock Events
| Event | Date | Price (ā¬) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 130 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:30 | In 41 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 40 days | ||
| General meeting for 2026 | 2026-06-11 09:00 | 0.35 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 08:30 | 1.04 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 1.04 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:30 | 0.91 (+0.00%) | ||
| Annual report for 2025 | 2026-02-26 | 0.91 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 0.91 (+0.00%) |
Show
Entries
Heron Therapeutics Inc Frequently Asked Questions
What is Heron Therapeutics Inc(FRA:AXD2)'s stock price today?
The current price of FRA:AXD2 is ā¬0.35. The 52 week high of FRA:AXD2 is ā¬1.87 and 52 week low is ā¬0.33.
When is next earnings date of Heron Therapeutics Inc(FRA:AXD2)?
The next earnings date of Heron Therapeutics Inc(FRA:AXD2) is 2026-08-07 Est..
Does Heron Therapeutics Inc(FRA:AXD2) pay dividends? If so, how much?
Heron Therapeutics Inc(FRA:AXD2) does not pay dividend.
Press Release
Articles on Heron Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers